Pub Date : 2023-03-01DOI: 10.1136/ejhpharm-2023-eahp.389
MJ Canalejo Fuentes, N. Herrero Muñoz, A. Ontañón Nasarre, M. García Gil
{"title":"4CPS-080 Optimisation of antiretroviral therapy: results after simplification to bitherapy with dolutegravir/lamivudine or dolutegravir/rilpivirine","authors":"MJ Canalejo Fuentes, N. Herrero Muñoz, A. Ontañón Nasarre, M. García Gil","doi":"10.1136/ejhpharm-2023-eahp.389","DOIUrl":"https://doi.org/10.1136/ejhpharm-2023-eahp.389","url":null,"abstract":"","PeriodicalId":19619,"journal":{"name":"Oral Presentations - Late-Breaking Proffered Abstracts","volume":"27 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86556187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-03-01DOI: 10.1136/ejhpharm-2023-eahp.399
R. Vida, M. Auer, M. Jancsó, N. Schaadt, A. Somogyi-Végh, L. Botz
Background and ImportanceIn recent years not just the novel therapeutic approaches, but the Coronavirus pandemic has also affected the therapy management of patients with rheumatoid arthritis. Beside these changes, the immunisation against COVID-19 has also been an issue and raised several questions from clinicians to patients.Aim and ObjectivesTherefore, our aim was to find out the possible changes that patients were experiencing and the potential factors influencing their therapy.Material and MethodsData was collected through structured personal interviews with a 33-item questionnaire licensed by the Regional Research Ethics Committee of the University of Pécs and review of the medical records from January until September in 2022. We used the data available in the ambulatory medical records and the itemised reporting interface of the National Health Insurance Fund. Drug interactions were analysed using UpToDate Lexicomp database.Results35 female patients (average age: 63.53 years ± 13.82) and 23 male patients (average age: 53.54 ± 12.96) received biological or targeted therapy for an average of 7.17 years ( ± 4.12), while the average patient activity index DAS28 was 3.15 ( ± 1.17) and BASDAI was 5.29 ( ± 5.52). 87.93% (51/58) of the patients have used non-medication health products, mainly vitamin C or D. 34.48% of the patients were confirmed with coronavirus infection during the pandemic, while the vaccination rate was 87.89%. 83.45% of the patients received at least one mRNA vaccine. In our patient group, the influenza vaccination rate was 36.21%, while only 5.21% of the patients had been vaccinated against Pneumococcus in six months previous to our survey. The total number of serious (category X and D) interactions were 216, in 135 cases a vaccine and in 58 cases a monoclonal antibody or targeted therapy was included as interacting pair.Conclusion and RelevanceDespite the growing number of new therapeutic approaches and vaccines, the screening methods for analysing potential drug interaction are lacking behind and the Summary of Product Characteristics are not suitable for comprehensive evaluations. The inclusion of these therapies and the optimisation in vaccination status in the medication review process and the understanding of immunological mechanism potentially influencing the therapy of patients is warranted.References and/or AcknowledgementsConflict of InterestNo conflict of interest
{"title":"4CPS-112 Survey of dietary supplement use and vaccination status among rheumatoid arthritis patients during the COVID-19 pandemic","authors":"R. Vida, M. Auer, M. Jancsó, N. Schaadt, A. Somogyi-Végh, L. Botz","doi":"10.1136/ejhpharm-2023-eahp.399","DOIUrl":"https://doi.org/10.1136/ejhpharm-2023-eahp.399","url":null,"abstract":"Background and ImportanceIn recent years not just the novel therapeutic approaches, but the Coronavirus pandemic has also affected the therapy management of patients with rheumatoid arthritis. Beside these changes, the immunisation against COVID-19 has also been an issue and raised several questions from clinicians to patients.Aim and ObjectivesTherefore, our aim was to find out the possible changes that patients were experiencing and the potential factors influencing their therapy.Material and MethodsData was collected through structured personal interviews with a 33-item questionnaire licensed by the Regional Research Ethics Committee of the University of Pécs and review of the medical records from January until September in 2022. We used the data available in the ambulatory medical records and the itemised reporting interface of the National Health Insurance Fund. Drug interactions were analysed using UpToDate Lexicomp database.Results35 female patients (average age: 63.53 years ± 13.82) and 23 male patients (average age: 53.54 ± 12.96) received biological or targeted therapy for an average of 7.17 years ( ± 4.12), while the average patient activity index DAS28 was 3.15 ( ± 1.17) and BASDAI was 5.29 ( ± 5.52). 87.93% (51/58) of the patients have used non-medication health products, mainly vitamin C or D. 34.48% of the patients were confirmed with coronavirus infection during the pandemic, while the vaccination rate was 87.89%. 83.45% of the patients received at least one mRNA vaccine. In our patient group, the influenza vaccination rate was 36.21%, while only 5.21% of the patients had been vaccinated against Pneumococcus in six months previous to our survey. The total number of serious (category X and D) interactions were 216, in 135 cases a vaccine and in 58 cases a monoclonal antibody or targeted therapy was included as interacting pair.Conclusion and RelevanceDespite the growing number of new therapeutic approaches and vaccines, the screening methods for analysing potential drug interaction are lacking behind and the Summary of Product Characteristics are not suitable for comprehensive evaluations. The inclusion of these therapies and the optimisation in vaccination status in the medication review process and the understanding of immunological mechanism potentially influencing the therapy of patients is warranted.References and/or AcknowledgementsConflict of InterestNo conflict of interest","PeriodicalId":19619,"journal":{"name":"Oral Presentations - Late-Breaking Proffered Abstracts","volume":"41 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88232856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-03-01DOI: 10.1136/ejhpharm-2023-eahp.464
R. O'Hare, S. Gilespie, S. Haughey
{"title":"6ER-003 The climate emergency, how can pharmacy make a difference?","authors":"R. O'Hare, S. Gilespie, S. Haughey","doi":"10.1136/ejhpharm-2023-eahp.464","DOIUrl":"https://doi.org/10.1136/ejhpharm-2023-eahp.464","url":null,"abstract":"","PeriodicalId":19619,"journal":{"name":"Oral Presentations - Late-Breaking Proffered Abstracts","volume":"9 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81704446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-03-01DOI: 10.1136/ejhpharm-2023-eahp.370
R. Barbosa, S. Fraga, C. Sampaio, L. Sousa, P. Soares, C. Barbosa
{"title":"3PC-030 Evaluation of excipients used in paediatric compounded formulations prescribed in a neonatal intensive care unit","authors":"R. Barbosa, S. Fraga, C. Sampaio, L. Sousa, P. Soares, C. Barbosa","doi":"10.1136/ejhpharm-2023-eahp.370","DOIUrl":"https://doi.org/10.1136/ejhpharm-2023-eahp.370","url":null,"abstract":"","PeriodicalId":19619,"journal":{"name":"Oral Presentations - Late-Breaking Proffered Abstracts","volume":"24 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76634258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-03-01DOI: 10.1136/ejhpharm-2023-eahp.466
H. Rodríguez-Ramallo, N. Báez Gutiérrez, B. Aparicio Castellano, A. Rodríguez Pérez, B. Santos Ramos, L. Rodríguez Defrancisco, M. Fernández González
{"title":"6ER-012 Treatment decisions according to 1-year risk mortality in pulmonary arterial hypertension patients: a multicentre retrospective study","authors":"H. Rodríguez-Ramallo, N. Báez Gutiérrez, B. Aparicio Castellano, A. Rodríguez Pérez, B. Santos Ramos, L. Rodríguez Defrancisco, M. Fernández González","doi":"10.1136/ejhpharm-2023-eahp.466","DOIUrl":"https://doi.org/10.1136/ejhpharm-2023-eahp.466","url":null,"abstract":"","PeriodicalId":19619,"journal":{"name":"Oral Presentations - Late-Breaking Proffered Abstracts","volume":"58 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73310305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-03-01DOI: 10.1136/ejhpharm-2023-eahp.380
A. Peláez Bejarano, E. Rodrigues Molins, L. Gómez-Sayago
{"title":"4CPS-035 Association of dihydropyrimidine dehydrogenase deficiency with capecitabine tolerance","authors":"A. Peláez Bejarano, E. Rodrigues Molins, L. Gómez-Sayago","doi":"10.1136/ejhpharm-2023-eahp.380","DOIUrl":"https://doi.org/10.1136/ejhpharm-2023-eahp.380","url":null,"abstract":"","PeriodicalId":19619,"journal":{"name":"Oral Presentations - Late-Breaking Proffered Abstracts","volume":"115 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79114916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-03-01DOI: 10.1136/ejhpharm-2023-eahp.458
V. González Rosa, AB Morillo Mora, C. Muñoz Cid, M. Zaragoza Rascón, J. González-Miret Martín
{"title":"5PSQ-126 Effectiveness and safety of omalizumab, mepolizumab and benralizumab in patients with severe uncontrolled asthma","authors":"V. González Rosa, AB Morillo Mora, C. Muñoz Cid, M. Zaragoza Rascón, J. González-Miret Martín","doi":"10.1136/ejhpharm-2023-eahp.458","DOIUrl":"https://doi.org/10.1136/ejhpharm-2023-eahp.458","url":null,"abstract":"","PeriodicalId":19619,"journal":{"name":"Oral Presentations - Late-Breaking Proffered Abstracts","volume":"313 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80031294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-03-01DOI: 10.1136/ejhpharm-2023-eahp.432
A. Gracia Moya, S. Garcia Garcia, M. Miarons Font, JM Del Río Gutiérrez, A. Pau Parra, ML Perez Rodriguez, M. L. Lalueza Broto, M. G. Gorgas Torner
{"title":"4CPS-252 Optimisation of ertapenem posology in a critically ill patient by therapeutic drug monitoring: a case report","authors":"A. Gracia Moya, S. Garcia Garcia, M. Miarons Font, JM Del Río Gutiérrez, A. Pau Parra, ML Perez Rodriguez, M. L. Lalueza Broto, M. G. Gorgas Torner","doi":"10.1136/ejhpharm-2023-eahp.432","DOIUrl":"https://doi.org/10.1136/ejhpharm-2023-eahp.432","url":null,"abstract":"","PeriodicalId":19619,"journal":{"name":"Oral Presentations - Late-Breaking Proffered Abstracts","volume":"18 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80195467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-03-01DOI: 10.1136/ejhpharm-2023-eahp.373
J. Esquivel Negrín, P. Joy Carmona, A. Martín López, MÁ Ocaña Gómez, M. Ríos De Paz, M. D. De Dios García, B. del Rosario García, EG Fernández López, T. Betancor García, J. Merino Alonso
{"title":"4CPS-001 Emicizumab in acquired haemophilia type A: a case report","authors":"J. Esquivel Negrín, P. Joy Carmona, A. Martín López, MÁ Ocaña Gómez, M. Ríos De Paz, M. D. De Dios García, B. del Rosario García, EG Fernández López, T. Betancor García, J. Merino Alonso","doi":"10.1136/ejhpharm-2023-eahp.373","DOIUrl":"https://doi.org/10.1136/ejhpharm-2023-eahp.373","url":null,"abstract":"","PeriodicalId":19619,"journal":{"name":"Oral Presentations - Late-Breaking Proffered Abstracts","volume":"20 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80323307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-03-01DOI: 10.1136/ejhpharm-2023-eahp.375
Á. Narrillos Moraza, E. González-Haba Peña, M. Sánchez Fresneda, C. Martínez Fernández-Llamazares, S. Manrique Rodríguez, I. Taladriz Sender, A. Herranz Alonso, M. Sanjurjo Sáez
{"title":"4CPS-013 Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in children with sickle cell disease: efficacy and safety","authors":"Á. Narrillos Moraza, E. González-Haba Peña, M. Sánchez Fresneda, C. Martínez Fernández-Llamazares, S. Manrique Rodríguez, I. Taladriz Sender, A. Herranz Alonso, M. Sanjurjo Sáez","doi":"10.1136/ejhpharm-2023-eahp.375","DOIUrl":"https://doi.org/10.1136/ejhpharm-2023-eahp.375","url":null,"abstract":"","PeriodicalId":19619,"journal":{"name":"Oral Presentations - Late-Breaking Proffered Abstracts","volume":"16 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73906363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：